Gene Predictis
About Gene Predictis
Gene Predictis is a company based in Lausanne (Switzerland) was acquired by NIMGenetics in February 2023. Gene Predictis operates in a competitive market with competitors including 23andMe, MedGenome, Foundation Medicine, Personalis and Veritas Genetics, among others.
- Headquarter Lausanne, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
NIMGenetics
(Feb 13, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Gene Predictis
Detailed funding history for Gene Predictis
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Gene Predictis
Gene Predictis has secured backing from 1 investor. Prominent investors backing the company include NIMGenetics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diagnostic solutions are developed using microarray and next-generation sequencing technologies.
|
Locked | Locked | Locked |
Investor details for Gene Predictis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gene Predictis
Investment portfolio details for Gene Predictis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gene Predictis
Detailed financials for Gene Predictis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gene Predictis Comparisons
Peer comparison for Gene Predictis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gene Predictis
Gene Predictis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 23andMe, MedGenome, Foundation Medicine, Personalis and Veritas Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
|
|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genetic testing products for health risks and traits are offered.
|
|
| Locked | Locked | Locked |
Personalized cancer diagnostics are developed using genomic big data analysis.
|
Detailed competitors of Gene Predictis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gene Predictis
Complete news archive for Gene Predictis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gene Predictis
Gene Predictis is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Based in Lausanne, Switzerland, Gene Predictis operates in the genomics sector, where tests for personalized medicine are developed. Focus is placed on screening for disease development risks and adverse drug reactions. Products encompass predictions for overall drug sensitivities, including irinotecan, carbamazepine, clopidogrel, and others, alongside nutrigenomics and inherited factors. Inherited risk tests cover thrombosis, cardiovascular conditions, deep-vein thrombosis, pulmonary embolism, osteoporosis, and further areas like auto-immune diseases and intolerances.
Gene Predictis's top competitors include 23andMe, Foundation Medicine and MedGenome.
Gene Predictis has 1 investor. Key investors include NIMGenetics.